Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle cell therapy drought ends
source: JAMA
year: 2017
authors: Voelker R
summary/abstract:After nearly 20 years without new treatments for sickle cell disease, the FDA has approved L-glutamine oral powder to reduce severe complications of the blood disorder in patients aged 5 years or older. It also is the first sickle cell disease treatment approved for pediatric patients.
Marketed as Endari, L-glutamine is an amino acid that can help prevent sickle red blood cells from sticking to the endothelial cells of blood vessels, which causes vaso-occlusion that results in severe pain and organ damage. Previously, the antimetabolite hydroxyurea had been the only FDA-approved drug for sickle cell disease.
DOI: 10.1001/jama.2017.10152read more full text
Related Content
-
Translating sickle cell guidelines into practice for primary care providers with Project ECHOBackground: Approximately 100,000 perso...
-
Guideline Information for PatientsLiving with chronic pain can be devastat...
-
Winfred C. Wang, MDDr. Winfred Wang is a pediatric hematolo...
-
Jessica Heath Templet, PAJessica Heath Templet is a certified Phy...
-
University Hospitals Seidman Cancer CenterUniversity Hospitals Seidman Cancer Cent...
-
Annual National Sickle Cell Disease Association of America (SCDAA) ConventionThe 51st Annual National Convention will...
-
Rare Diseases and Orphan Products Breakthrough SummitEach year, the NORD Summit, one of the l...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.